Randomized Controlled Trial of Proton Beam Radiotherapy Plus Sorafenib vs. Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria
Interventional
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall survival
On average followed for 5 years
No
Michael deVera, MD
Principal Investigator
Loma Linda University Medical Center
United States: Institutional Review Board
51000104
NCT01141478
August 2010
June 2016
Name | Location |
---|---|
Loma Linda University Medical Center | Loma Linda, California 92354 |